王陶陶  

发明专利

1. 王陶陶，董亚琳，王楚慧，陈思颖，孙金钥，王光启，曾卫东。一种个体化用药调整剂量的自动确定方法及系统。2025年04月11日，中国，ZL202510112928.7。
2. 王陶陶，董亚琳，孙金钥，王楚慧，陈思颖，杜倩，​​​​​​​曾卫东，王光启。个体化用药血药浓度预测算法的辅助生成方法及系统。2025年08月12日，中国，ZL202510366033.6。

代表性论著

1. Jiaojiao Chen, Quanfang Wang, Sihan Li, Ruiying Han, Chuhui Wang, Shiqi Cheng, Baogui Yang, Lizhuo Diao, Tingting Yang, Dan Sun, Di Zhang, Yalin Dong*, Taotao Wang*. Does Two-Step Infusion Improve the Pharmacokinetics/Pharmacodynamics Target Attainment of Meropenem in Critically Ill Patients? J Pharm Sci. 2024;113(9):2904-2914.
2. Quanfang Wang, Yuefeng Sun, Shidi Zhao, Chuqi Bai, Zhiwei Cong, Yalin Dong, Taotao Wang. Metallo-β-lactamases immobilized by magnetic zeolitic imidazolate frameworks-8 for degradation of β-lactam antibiotics in an aqueous environment. RSC Adv. 2023;13(49):34884-34890.
3. Quanfang Wang, Sihan Li, Jiaojiao Chen, Luting Yang, Yulan Qiu, Qian Du, Chuhui Wang, Mengmeng Teng, Taotao Wang*, Yalin Dong*. A novel strategy for therapeutic drug monitoring: application of biosensors to quantify antimicrobials in biological matrices. J Antimicrob Chemother,2023,78:(11):2612-2629.
4. Taotao Wang^#, Liyan Miao^#, Hua Shao, Xiaohua Wei, Miao Yan, Xiaocong Zuo, Jun Zhang, Xin Hai, Guangjun Fan, Wei Wang, Linlin Hu, Jian Zhou, Yichang Zhao, Yueliang Xie, Jingjing Wang, Sixun Guo, Liu Jin, Hao Li, Hui Liu, Quanfang Wang, Jiaojiao Chen, Sihan Li, Yalin Dong*. Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study. Int J Antimicrob Agents, 2022;60(5-6):106692.
5. Chen Jiaojiao, Li Sihan, Wang Quanfang, Wang Chuhui, Qiu Yulan, Yang Luting, Han Ruiying, Du Qian, Chen Lei, Dong Yalin*, Wang Taotao*. Optimizing Antimicrobial Dosing for Critically Ill Patients with MRSA Infections: A New Paradigm for Improving Efficacy during Continuous Renal Replacement Therapy. Pharmaceutics, 2022, 14(4), 842.
6. Yuzhu Dong, Dan Sun, Yan Wang, Qian Du, Ying Zhang, Ruiying Han, Mengmeng Teng, Tao Zhang, Lei Shi, Gezhi Zheng, Yalin Dong*, Taotao Wang*. Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure. BMC Infect Dis. 2022;22(1):23.
7. Taotao Wang, Miao Yan, Dan Tang, Yuzhu Dong, Li Zhu, Qian Du, Dan Sun, Jianfeng Xing, Yalin Dong*. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis. Pharmacotherapy. 2021;41(2):172-183.
8. Ruiying Han, Dan Sun, Sihan Li, Jiaojiao Chen, Mengmeng Teng, Bo Yang, Yalin Dong*, Taotao Wang*. Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients. Antibiotics (Basel). 2021;10(8):993.
9. Dong Yuzhu, Li Ying, Zhang Ying, Sun Dan, Du Qian, Zhang Tao, Teng Mengmeng, Han Ruiying, Wang Yan, Zhu Li, Lei Jin’e, Dong Yalin*, Wang taotao*. Clinical Efficacy and Cost-Effectiveness of beta-Lactam/beta-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients with Gram-Negative Bacteria Bloodstream Infection. Infection and drug resistance. 2020; 13:1327-1338.
10. Dong YZ, Li Y, Zhang Y, Zhang T, Zhu L, Dong YL*, Wang TT*. Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment. Basic Clin Pharmacol Toxicol. 2019;125(4):353-359.
11. Wang TT, Yan M, Tang D, Xue L, Zhang T, Dong YZ, Zhu L, Wang XG, Dong YL*. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis. J Clin Pharm Ther, 2018; 43(6):849-854.
12. 王陶陶, 胡萨萨, 尤海生, 陈思颖, 陈丽梅, 董海燕, 董亚琳*. 恶性血液病患者中伏立康唑血药浓度监测及其影响因素的探讨. 中国医院药学杂志, 2018; 38(7): 693-696+707.
13. 王陶陶, 陈思颖, 尤海生, 董海燕, 王雪, 董亚琳*. 侵袭性真菌感染患者伏立康唑肝毒性的研究. 中国药学杂志, 2018; 53(4): 290-294.
14. Lei JE, Xu JR*, Wang TT*. In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study. J Mycol Med, 2018; 28(2): 310-313. (IF=1.606)
15. You HS, Dong YZ, Zou YM, Zhang T, Lei JE, Chen LM, Wang X, Dong YL, Wang TT*. Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations. Int J Clin Pharmacol Ther, 2018; 56(5): 239-246.
16. Wang TT, Zhang T, Meng T, Li Y, Chen L, Yang QT, Dong HY, Lei JE, Chen LM, Dong YL*. A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model. J Transl Med, 2018; 16(1): 157.
17. Wang TT, Yan M, Tang D, Xue L, Zhang T, Dong YZ, Zhu L, Wang XG, Dong YL*. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh Class B and C Cirrhosis: a multicenter study. Int J Infect Dis, 2018; 72:49-54.
18. Wang TT, Yang QT, Wang Y, Li Y, Meng T, Chen L, Xie J, Xing JF, Dong YL*. Determination and characterization of the uptake of voriconazole in human lung epithelial cells by high-performance liquid chromatography-tandem mass spectrometry. Analytical Letters, 2017; 50(2): 304-314.
19. Wang TT, Yang QT, Chen L, Li Y, Meng T, Wang Y, Zhang T, Lei JE, Xing JF, Dong YL*. Uptake and efflux kinetics, and intracellular activity of voriconazole against A. fumigatus in human pulmonary epithelial cells: a new application for preventing invasive pulmonary aspergillosis[J]. Fundam Clin Pharmacol, 2017; 31(3): 311-318.
20. Wang TT, Xie J, Wang Y, Zheng XW, Lei JE, Wang X, Dong HY, Yang QT, Chen L, Xing JF, Dong YL*. Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections. Pharmacotherapy, 2015; 35(9): 797-804.
21. Wang TT, Li N, Hu SS, Xie J, Lei JE, Wang Y, Zheng XW, Xing JF, Dong YL*. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections. Int J Clin Pharmacol Ther, 2015; 53(5):356-362.
22. 王陶陶, 孙金钥, 陈思颖, 蔡江霞, 程晓亮, 王雪, 董海燕, 董亚琳*. 侵袭性真菌感染患者伏立康唑群体药动学研究及给药方案优化.中国药学杂志, 2014; 49(3):227-233.
23. Wang TT^#, Chen SY^#, Sun JY, Cai JX, Cheng XL, Dong HY, Wang X, Xing JF, Dong WH, Yao HP, Dong YL*. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chemother, 2014; 69(2): 463-470.​​​​​​​
24. Wang TT, Zhu HF, Sun JY, Cheng XL, Xie J, Dong HY, Chen LM, Wang X, Xing JF*, Dong YL*. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents, 2014; 44(5): 436-442.